Protecting bone health during cancer radiation therapy
Targeting the HIF-2 Signaling Pathway as a Radioprotective Strategy for Bone
This study is looking at ways to keep your bones healthy during radiation therapy for cancer by understanding how low oxygen levels affect bone cells, which could lead to new treatments that help prevent fractures while you’re being treated.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10846605 on NIH RePORTER |
What this research studies
This research investigates how to protect healthy bone tissue from damage caused by radiation therapy in cancer patients. It focuses on understanding the role of hypoxia and the HIF-2 signaling pathway in the bone microenvironment, which may help improve bone health during and after radiation treatment. By exploring unique cellular mechanisms, the research aims to find new therapeutic strategies that could reduce the risk of fractures in patients receiving radiotherapy. The approach includes studying the behavior of multipotent mesenchymal progenitors in response to radiation and low oxygen levels.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are scheduled to receive radiation therapy and are at risk for bone damage.
Not a fit: Patients who are not undergoing radiation therapy or those with pre-existing severe bone conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the risk of bone fractures in cancer patients undergoing radiation therapy.
How similar studies have performed: Other research has shown promising results in targeting cellular mechanisms for radioprotection, suggesting that this approach could be effective.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Wu, Colleen — Duke University
- Study coordinator: Wu, Colleen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.